NVCR Logo

NovoCure Limited (NVCR) 

NASDAQ
Market Cap
$1.96B
Sector
Healthcare
Industry
Medical—Instruments & Supplies
Rank in Sector
645 of 776
Rank in Industry
43 of 48

Largest Insider Buys in Sector

NVCR Stock Price History Chart

NVCR Stock Performance

About NovoCure Limited

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver …

Insider Activity of NovoCure Limited

Over the last 12 months, insiders at NovoCure Limited have bought $0 and sold $277,704 worth of NovoCure Limited stock.

On average, over the past 5 years, insiders at NovoCure Limited have bought $433,297 and sold $52.5M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 4,974 shares for transaction amount of $509,539 was made by Danziger Asaf (Chief Executive Officer) on 2021‑11‑26.

List of Insider Buy and Sell Transactions, NovoCure Limited

2024-11-02SaleChief Operating Officer
44
<0.0001%
$16.69$7340.00%
2024-11-01SaleEVP, Pres., Novocure Oncology
598
0.0005%
$15.94$9,531+2.53%
2024-11-01SaleChief Operating Officer
160
0.0001%
$15.88$2,540+2.53%
2024-10-31SaleChief Human Resources Officer
810
0.0008%
$15.79$12,792+7.94%
2024-08-02SaleChief Financial Officer
688
0.0006%
$20.14$13,857-17.43%
2024-06-04Saledirector
964
0.0009%
$23.89$23,033-21.03%
2024-06-04Saledirector
964
0.0009%
$23.89$23,025-21.03%
2024-06-04Saledirector
964
0.0009%
$23.89$23,027-21.03%
2024-03-04SaleChief Operating Officer
1,217
0.0011%
$16.01$19,484+2.86%
2024-03-04SaleEVP, Pres., Novocure Oncology
840
0.0008%
$16.01$13,448+2.86%
2024-03-01SaleChief Operating Officer
2,107
0.0019%
$16.03$33,769+4.00%
2024-03-01SaleEVP, Pres., Novocure Oncology
1,679
0.0015%
$16.03$26,909+4.00%
2024-02-28SaleChief Operating Officer
2,303
0.0022%
$16.14$37,177+5.46%
2024-02-28SaleEVP, Pres., Novocure Oncology
2,078
0.002%
$16.14$33,545+5.46%
2023-11-07SaleChief Growth Officer
382
0.0004%
$12.65$4,832+19.57%
2023-09-01SaleChief Operating Officer
294
0.0003%
$21.82$6,414-33.09%
2023-09-01SaleChief Growth Officer
273
0.0003%
$21.82$5,956-33.09%
2023-09-01SaleChief Financial Officer
883
0.0008%
$21.82$19,265-33.09%
2023-08-02SaleChief Financial Officer
1,144
0.0011%
$30.25$34,607-49.96%
2023-03-07SalePresident, CNS Cancers US
8,318
0.0079%
$75.16$625,205-73.25%

Insider Historical Profitability

29.19%
Shah PriteshChief Growth Officer
124511
0.1151%
$18.12150+85.52%
Perlhagen Gert L.director
6125000
5.6608%
$18.1211+171.79%
MYLOD ROBERT J JRdirector
20000
0.0185%
$18.1210<0.0001%
Danziger AsafChief Executive Officer
13583
0.0126%
$18.12255<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Fidelity Investments$251.08M14.9316.06M+0.63%+$1.58M0.02
The Vanguard Group$156.67M9.3210.02M+2.71%+$4.14M<0.01
BlackRock$141.99M8.449.08M+3.33%+$4.57M<0.01
Capital International Investors$138.55M8.248.86M+0.03%+$34,714.230.03
State Street$52.56M3.133.36M-12.96%-$7.83M<0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.